Events

ChemMedChem Symposium w/ Nathan Brown

Using Artificial Intelligence to Optimise Small-Molecule Drug Design

The concept of in silico molecular design goes back decades and has a long history of published approaches using many different algorithms and models [1,2]. Major challenges involved in de novo molecular design are manifold, including identifying appropriate molecular representations for optimisation, scoring designed molecules against multiple modelled endpoints, and objectively quantifying synthetic feasibility of the designed structures.

Recently, multiobjective de novo design, more recently referred to as generative chemistry, has had a resurgence of interest. This renaissance has highlighted a step-change in successful applications of such methods. This presentation will review the development of de novo design methods over the years including the author’s original work in this area from the early 2000s [3], to recent approaches that show great promise [4,5]. Through this review, improvements in important components of de novo design, including machine learning model predictions and automated synthesis planning, will also be presented.

→ Register here


Nathan Brown

Head of ChemoInformatics at BenevolentAI

Nathan is recognised as a global thought-leader in Chemoinformatics and computational drug discovery, and is the inventor of the first multiobjective de novo molecular design system. He joined BenevolentAI in 2017 from The Institute of Cancer Research, London where he founded and led the In Silico Medicinal Chemistry team for over ten years, with significant scientific impact on drugs in active clinical trials, and the development of new algorithms for drug discovery. Nathan has published over 40 papers and three books; is a Fellow of The Royal Society of Chemistry; and is the 2017 recipient of the Corwin Hansch Award.


More Posts

You Might Also Like

Blog
Intern at BenevolentAI part I: meet our 2020 intern cohort
What impactful work did our interns get up to across Engineering, Data Science, ML and business operations this summer? Get to know them and their work in our tech internships blog.
Nov 26, 2020
News
FDA grants Emergency Use Authorisation for baricitinib in hospitalised COVID-19 patients nine months after initial hypothesis was published by BenevolentAI
BenevolentAI scientists first identified baricitinib as a potential treatment for COVID-19 in early February 2020 using Benevolent's AI tools and biomedical knowledge graph.
Nov 20, 2020
News
BenevolentAI at NeurIPS 2020: Machine Learning in Drug Discovery
BenevolentAI is happy to announce it is sponsoring NeurIPS 2020. Join us to hear about data diversity and ML applied drug discovery, and to learn about careers in the field.
Nov 17, 2020
Blog
Careers with Impact: 5 learnings from machine learning applied drug discovery
Last week, we brought together four of our exceptional colleagues for a panel discussion on careers in machine learning applied drug discovery. Here are some of our main takeaways:
Nov 17, 2020
Blog
Data published in Science Advances shows baricitinib reduces COVID-19 morbidity and mortality
Research published in Science Advances supports BenevolentAI’s AI-generated hypothesis from late January for baricitinib as a treatment for COVID-19.
Nov 13, 2020
News
Sir Nigel Shadbolt joins BenevolentAI as a non-executive director
BenevolentAI strengthens its Board with the appointment of AI pioneer Sir Nigel Shadbolt as Non-Executive Director.
Nov 3, 2020